Literature DB >> 523366

Tobramycin nephrotoxicity. A prospective clinical study.

A Coca, J Blade, A Martinez, F Segura, E Soriano, M Ribas-Mundo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 523366      PMCID： PMC2425802          DOI： 10.1136/pgmj.55.649.791

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  29 in total

1.  The nephrotoxicity of antimicrobial agents (second of three parts).

Authors:  G B Appel; H C Neu
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

2.  Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States.

Authors:  A Z Lane; G E Wright; D C Blair
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

3.  Acute renal failure during cephalothin therapy.

Authors:  J R Burton; N S Lichtenstein; R B Colvin; N E Hyslop
Journal:  JAMA       Date:  1974-08-05       Impact factor: 56.272

4.  Acute renal failure after high doses of gentamicin and cephalothin.

Authors:  D Kleinknecht; D Ganeval; D Droz
Journal:  Lancet       Date:  1973-05-19       Impact factor: 79.321

5.  Preclinical toxicology studies with tobramycin.

Authors:  J S Welles; J L Emmerson; W R Gibson; R Nickander; N V Owen; R C Anderson
Journal:  Toxicol Appl Pharmacol       Date:  1973-07       Impact factor: 4.219

6.  Anuria and acute tubular necrosis associated with gentamicin and cephalothin.

Authors:  S N Bobrow; E Jaffe; R C Young
Journal:  JAMA       Date:  1972-12-18       Impact factor: 56.272

7.  Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail.

Authors:  W K Lau; L S Young; R E Black; D J Winston; S R Linne; R J Weinstein; W L Hewitt
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

8.  Nebramycin, a new broad-spectrum antibiotic complex. IV. In vitro and in vivo laboratory evaluation.

Authors:  W E Wick; J S Welles
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

9.  Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin.

Authors:  S A Lerner; R Seligsohn; G J Matz
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

10.  Nephrotoxicity from cancer immunotherapy.

Authors:  G M Dosik; J U Gutterman; E M Hersh; M Akhtar; T Sonoda; R G Horn
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391
View more
  4 in total

1.  Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin.

Authors:  J M Gatell; J G San Miguel; L Zamora; V Araujo; M Bonet; M Bohé; M T Jimenez de Anta; M Farré; M Elena; A Ballesta; J L Marin
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 2.  Comparison of drug dosing methods.

Authors:  M E Burton; M R Vasko; D C Brater
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

3.  Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin.

Authors:  J M Gatell; J G SanMiguel; V Araujo; L Zamora; J Maña; M Ferrer; M Bonet; M Bohe; M T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

4.  Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii.

Authors:  Reem E Alarfaj; Manal M Alkhulaifi; Ahmed J Al-Fahad; Shokran Aljihani; Alaa Eldeen B Yassin; Majed F Alghoribi; Majed A Halwani
Journal:  Pharmaceutics       Date:  2022-01-05       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.